Exploring ways to prevent multiple myeloma in patients with a precursor condition.
Addressing racial disparities in monoclonal gammopathy of undetermined significance and progression to multiple myeloma from a prevention perspective
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-10442544
This study is looking at whether the diabetes medication metformin can help prevent people with a condition called MGUS from developing multiple myeloma, especially focusing on African American patients who are at greater risk, and it aims to find new ways to improve health outcomes for everyone involved.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10442544 on ClinicalTrials.gov |
What this research studies
This research investigates the use of metformin, a common diabetes medication, to prevent the progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM), particularly focusing on the racial disparities observed in these conditions. The study aims to understand how metformin can help reduce the risk of developing MM, especially in African American patients who are at a higher risk. By analyzing the effects of metformin on weight loss and its potential benefits in MGUS patients, the research seeks to provide new intervention strategies that could improve patient outcomes. The approach includes monitoring participants' health and analyzing data to assess the effectiveness of metformin in preventing disease progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults with monoclonal gammopathy of undetermined significance, especially those who are African American or have obesity.
Not a fit: Patients who do not have MGUS or those with advanced multiple myeloma will not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective prevention strategies for multiple myeloma, particularly benefiting high-risk populations.
How similar studies have performed: Previous research has shown promising results using metformin for various conditions, suggesting potential success in this novel application.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHANG, SU-HSIN — WASHINGTON UNIVERSITY
- Study coordinator: CHANG, SU-HSIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer